Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 887 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EPOCH II Clear all

Conditions: Cancer
Interventions: Fentanyl sublingual spray, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chandler, Arizona

Conditions: Alternating Hemiplegia of Childhood
Interventions: Sodium Oxybate; Drug
Lead sponsor: University of Utah; Other
Eligibility: 6 Months to 25 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 6,448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Graft-versus-Host Disease
Interventions: Bortezomib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cow's Milk Allergy
Interventions: Baked non-fat cow's milk powder, Placebo: Tapioca Powder; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Years to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Cancer
Interventions: Pralatrexate With Vitamin B12 and Folic Acid; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Irinotecan; Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Santa Fe, New Mexico

Conditions: Uveitis
Interventions: Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab); Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax, cBTKi Monotherapy; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 20
States / cities: Springdale, Arkansas • Aurora, Colorado • Jacksonville, Florida + 17 more

Conditions: Glucose, High Blood
Interventions: Human Insulin, Finger-actuated, Metered Pump Sprayer; Biological · Device
Lead sponsor: Transdermal Delivery Solutions Corp; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Palm Beach Gardens, Florida

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Ovarian Cancer, Psychosocial Effects of Cancer and Its Treatment, Sarcoma
Interventions: educational intervention, informational intervention, internet-based intervention, questionnaire administration, study of socioeconomic and demographic variables, survey administration, psychosocial assessment and care, quality-of-life assessment, standard follow-up care; Other · Procedure
Lead sponsor: Tufts Medical Center; Other
Eligibility: 2 Months to 18 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Duarte, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more

Conditions: Breast Cancer, Hot Flashes, Hot Flushes
Interventions: soy protein, isoflavones, Tamoxifen, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 14
States / cities: Rockford, Illinois • Elkhart, Indiana • Kokomo, Indiana + 9 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK1292263, GSK1292263 matching placebo, Sitagliptin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Chula Vista, California • Miami, Florida + 4 more

Conditions: HIV Infections, HCV, Overdose
Interventions: Ganchero intervention; Behavioral
Lead sponsor: North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI); Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Obesity
Interventions: Phase II: Lifestyle treatment, Phase II: Control treatment, Phase I: Observational studies; Behavioral · Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 22 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Obsessive-Compulsive Disorder
Interventions: Summit RC+S System, One Month Blinded Discontinuation Period:; Device · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas

Conditions: Esophageal Cancer, Gastric Cancer, GE Junction Cancer
Interventions: Taxotere, Cisplatin, Irinotecan; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Metastatic Colorectal Cancer
Interventions: mFOLFOX6, MVA-BN-CV301, FPV-CV301, Nivolumab; Drug · Biological
Lead sponsor: Patrick Boland; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Duarte, California • Miami, Florida • Westwood, Kansas + 4 more

Conditions: Systemic Lupus Erythematosus
Interventions: Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Myelofibrosis
Interventions: APLIDIN (plitidepsin); Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: financial incentives; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 30 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)
Interventions: Physician's Choice, Tebentafusp; Drug
Lead sponsor: Sarcoma Alliance for Research through Collaboration; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: Tifeglipron, Semaglutide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Tucson, Arizona • Lake Forest, California • Rancho Cucamonga, California + 21 more

Search by objective public record fields.

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

Baked Milk Oral Immunotherapy for Cow's Milk Allergy

Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

Dose Response Study of Transdermal Human Insulin in Patients

A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families

Soy Protein Supplement In Treating Hot Flashes in Postmenopausal Women Receiving Tamoxifen for Breast Disease

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

The Liver Health Study for Patients with NAFLD

Development of Adaptive Deep Brain Stimulation for OCD

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis

Testing Strategies for Weight Loss, II

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 Diabetes